Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: A case report and review of the literature

Yvonne Efebera, Elizabeth Blanchard, Charles Allam, Andrew Han, Saem Lee, Nikhil Munshi

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Necrobiotic xanthogranuloma (NXG) was first described in 1980 by Kossard and Winkelmann in an article in which they discussed 8 patients with xanthomatous plaques who were noted to have monoclonal gammopathy, predominantly of the Ig(immunoglobulin)G-κ type. 1 Since then more than 50 patients with this disorder have been described, with approximately 80% of them having an associated monoclonal gammopathy. We describe the first case, to our knowledge, of NXG with associated monoclonal gammopathy treated with thalidomide plus dexamethasone, achieving complete resolution of the skin lesions and sustaining response more than 3 years after treatment.

Original languageEnglish (US)
Pages (from-to)298-302
Number of pages5
JournalClinical Lymphoma, Myeloma and Leukemia
Volume11
Issue number3
DOIs
StatePublished - Jun 2011
Externally publishedYes

Keywords

  • MGUS
  • Multiple myeloma
  • Necrobiotic xanthogranuloma
  • Thalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Complete response to thalidomide and dexamethasone in a patient with necrobiotic xanthogranuloma associated with monoclonal gammopathy: A case report and review of the literature'. Together they form a unique fingerprint.

Cite this